Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
209 hedge funds and large institutions have $1.65B invested in Sage Therapeutics in 2022 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 62 increasing their positions, 71 reducing their positions, and 36 closing their positions.
53% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $12.5M
1.73% more ownership
Funds ownership: 84.58% → 86.31% (+1.7%)
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $1.65B → $1.65B (-$4.65M)
1% less funds holding
Funds holding: 211 → 209 (-2)
13% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 71
Top Buyers
| 1 |
BlackRock
New York
|
+$49.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$32.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.4M |
| 4 |
Goldman Sachs
New York
|
+$26.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$16.2M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$75.3M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$28M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$16.9M |
| 4 |
AG
Artal Group
Luxembourg
|
-$10.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$9.18M |
SAGE Hedge Fund Activity: Q2 2022 in Review
209 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2022, worth a combined $1.65B — down 0.28% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SAGE positions and 36 closed out — a net gain of 2 holders — while 62 added to existing stakes and 71 trimmed.
The largest buyer was BlackRock, adding an estimated $49.9M. The largest seller was Wellington Management Group, cutting an estimated $75.3M.
- 209 institutional investors held Sage Therapeutics (SAGE) as of Q2 2022, down from 211 in Q1 2022.
- Funds reported $1.65B of Sage Therapeutics stock for Q2 2022, down 0.28% quarter-over-quarter.
- 38 funds opened new Sage Therapeutics positions in Q2 2022 and 36 closed out, a net change of +2 holders.
- The largest Sage Therapeutics buyer in Q2 2022 was BlackRock, an estimated $49.9M added.
- The largest Sage Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $75.3M sold.
Based on aggregated 13F filings for Q2 2022.